DrugDashboards

Fyremadel

ganirelix acetate · GANIRELIX ACETATE 250 ug/.5mL · Injection, Solution · Subcutaneous · Ferring Pharmaceuticals Inc.

NDC 55566-1010-01 · 1 BLISTER PACK in 1 CARTON / 1 SYRINGE in 1 BLISTER PACK / .5 mL in 1 SYRINGE · ANDA · View full market →

The short version

7 companies supply this market — a reasonable cushion if one runs into trouble. The price has fallen 34% in a year, to $62.35 per mL — and generics that get this cheap tend to get abandoned rather than defended. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want. Historically, drugs in this position went on to a new shortage within 90 days about 0.4% of the time — roughly 3× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$50.00$100.00$150.00Aug 2024Dec 2025$62.35
17 price points · per ML · last surveyed Invalid DateSource: CMS NADAC

Estimated fill cost

WAC per package, as filed
$184.02
Reported to Texas DSHS · 2026 annual filing · Ferring Pharmaceuticals, Inc.

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Supply fragility

18Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • Class I/II recall on same molecule/form in past 12 months+8
  • sterile injectable+10

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.4%chance of a new FDA shortage posting for ganirelix acetate (injectable) in the next 90 days

sterile injectable · sole-source market · 1 Class I/II recall(s) in 12 months

For scale: the typical drug’s chance is about 0.1% — this one is 3× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA204246
TE code
AP
Approval date
Nov 30, 2018
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

  • Class II · TerminatedApr 19, 2023
    Sun Pharmaceutical Industries Ltd.Presence of Particulate Matter: A piece of glass was found in a prefilled syringe.

Manufacturers of ganirelix acetate (Injection, Solution)

LabelerStrengthFirst seenLast seen
Ferring Pharmaceuticals Inc.GANIRELIX ACETATE 250 ug/.5mLJul 15, 2026Sep 2, 2026
Gland Pharma LimitedGANIRELIX ACETATE 250 ug/.5mLJul 15, 2026Sep 2, 2026
Lupin Pharmaceuticals, Inc.GANIRELIX ACETATE 250 ug/.5mLJul 15, 2026Sep 2, 2026
Meitheal Pharmaceuticals Inc.GANIRELIX ACETATE 250 ug/.5mLJul 15, 2026Sep 2, 2026
Mullan Pharmaceutical Inc.GANIRELIX ACETATE 250 ug/.5mLJul 15, 2026Sep 2, 2026
Organon LLCGANIRELIX ACETATE 250 ug/.5mLJul 15, 2026Sep 2, 2026
Qilu Pharmaceutical Co., Ltd.GANIRELIX ACETATE 250 ug/.5mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Fyremadel — NDC 55566-1010-01," retrieved September 3, 2026, https://drugdashboards.com/drug/55566101001.

Free to cite with attribution — see how the data is put together.